A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma

被引：28

作者：

Honrubia, FM ^{[1
]}

Larsson, LI

Spiegel, D

机构：

[1] Hosp Miguel Servet, Serv Oftalmol, Zaragoza, Spain

[2] Pharmacia Corp, Stockholm, Sweden

[3] Univ Eye Hosp, Dept Ophthalmol, Regensburg, Germany

来源：

ACTA OPHTHALMOLOGICA SCANDINAVICA | 2002年 / 80卷 / 06期

关键词：

intraocular pressure; open-angle glaucoma; treatment; latanoprost; dorzolamide; timolol;

D O I：

10.1034/j.1600-0420.2002.800615.x

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To compare the effects on intraocular pressure (IOP) of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5%. Methods: Overall, 226 patients whose IOP was insufficiently controlled by timolol alone were randomized to receive either latanoprost once daily or the fixed combination of dorzolamide plus timolol twice daily. Intraocular pressure was measured at 10 : 00 am and 5 : 00 pm at baseline and after 3 months of treatment. Results: Mean IOP was reduced from baseline in both groups (p < 0.001), with a mean +/- SEM reduction of - 4.3 +/- 0.3 mmHg (19%) for the latanoprost treatment group and - 4.0 +/- 0.3 mmHg (17%) for the dorzolamide plus timolol treatment group. The two therapies were similarly effective in lowering IOP levels (mean difference in reduction: - 0.4 +/- 0.4; 95% confidence interval: - 1.1, 0.4). Conclusions: Monotherapy with latanoprost once daily was as effective in reducing mean IOP as the fixed combination of dorzolamide plus timolol twice daily in patients with IOP insufficiently controlled by timolol alone.

引用

页码：635 / 641

页数：7

共 29 条

[1] LATANOPROST ADMINISTERED ONCE-DAILY CAUSED A MAINTAINED REDUCTION OF INTRAOCULAR-PRESSURE IN GLAUCOMA PATIENTS TREATED CONCOMITANTLY WITH TIMOLOL [J].

ALM, A ;

WIDENGARD, I ;

KJELLGREN, D ;

SODERSTROM, M ;

FRISTROM, B ;

HEIJL, A ;

STJERSCHANTZ, J .

BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (01) :12-16

[2] Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol [J].

Alm, A ;

Stjernschantz, J ;

Widengard, I ;

Linden, C ;

Soderstrom, M ;

Nilsson, SE ;

Fristrom, B ;

Lindblom, B ;

Heijl, A ;

Gundersen, KG ;

Ehinger, B ;

Holmin, C ;

BengtssonStigmar, E ;

Aasved, H ;

Jangard, P ;

Ringvold, A ;

Vegge, T ;

Halseide, R ;

LundAndersen, H ;

Flesner, P ;

Thygesen, J ;

Airaksinen, J ;

Tuulonen, A .

OPHTHALMOLOGY, 1995, 102 (12) :1743-1752

[3]

Asrani S, 2000, J GLAUCOMA, V9, P134

[4] Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting [J].

Barnebey, H ;

Kwok, SY .

CLINICAL THERAPEUTICS, 2000, 22 (10) :1204-1212

[5] A randomized trial comparing the dorzolamide-timolal combination given twice daily to monotherapy with timolol and dorzolamide [J].

Boyle, JE ;

Ghosh, K ;

Gieser, DK ;

Adamsons, IA .

OPHTHALMOLOGY, 1998, 105 (10) :1945-1951

[6]

Bucci MG, 1999, J GLAUCOMA, V8, P24

[7] Latanoprost, a prostaglandin analog, for glaucoma therapy - Efficacy and safety after 1 year of treatment in 198 patients [J].

Camras, CB ;

Alm, A ;

Watson, P ;

Stjernschantz, J ;

Aasved, H ;

Jangard, P ;

LundAndersen, H ;

Flesner, P ;

Soderstrom, M ;

Ehinger, B ;

Holmin, C ;

BengtssonStigmar, E ;

Heijl, A ;

Gundersen, KG ;

Airaksinen, J ;

Tuulonen, A ;

Halseide, R ;

Lindblom, B ;

Ringvold, A ;

Vegge, T ;

Linden, C ;

Nilsson, SE ;

Fristrom, B ;

Widengard, I ;

Thygesen, J ;

Green, F ;

Valenzuela, F ;

Potts, M ;

Spencer, I ;

Coakes, R ;

Reynolds, P ;

Mills, B ;

Chatterjee, A ;

Nagasubramanian, S ;

Roxburgh, S ;

Sanders, R ;

Bailey, M ;

Whyte, IF ;

Vernon, S ;

Sloper, M ;

Murray, S ;

Davey, C ;

HickmanCasey, J ;

Longstaff, S ;

Currie, Z ;

Wishart, P ;

Austin, M ;

Birch, M ;

Elkington, A ;

Luff, A .

OPHTHALMOLOGY, 1996, 103 (11) :1916-1924

[8] Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - A six-month, masked, multicenter trial in the United States [J].

Camras, CB ;

Cioffi, GA ;

VanBuskirk, EM ;

Fraser, J ;

Stewart, WC ;

Stewart, JA ;

Lustgarten, J ;

Schumer, RA ;

Podos, SM ;

Arroyo, M ;

Nitzberg, S ;

Ritch, R ;

Abundo, G ;

Caronia, R ;

Liebmann, J ;

Steinberger, D ;

Krupin, T ;

Rosenberg, LF ;

Ruderman, JM ;

Clarkson, K ;

Weinreb, RN ;

Ochabsi, R ;

Sherwood, M ;

Smith, MF ;

Stokes, DW ;

Zam, ZS ;

Wilensky, J ;

Hillman, D ;

Kaplan, B ;

Gates, V ;

Nail, C ;

Zimmerman, T ;

Fechtner, R ;

Fenton, R ;

Fenton, J ;

Higginbotham, EJ ;

Johnson, AT ;

PollackRundle, CJ ;

Weiss, E ;

Yablonski, ME ;

Tannenbaum, MH ;

Ibrahim, F ;

Ohia, E ;

Neely, D ;

Minckler, D ;

Heuer, D ;

Lee, P ;

Padea, M ;

Kaufman, PL ;

Heatley, GA .

OPHTHALMOLOGY, 1996, 103 (01) :138-147

[9] A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide [J].

Clineschmidt, CM ;

Williams, RD ;

Snyder, E ;

Adamsons, IA .

OPHTHALMOLOGY, 1998, 105 (10) :1952-1959

[10] Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension - A 3-month randomised study [J].

Emmerich, KH .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 238 (01) :19-23

← 1 2 3 →